Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
NCT02769169Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in polypoidal choroidal vasculopathy (PCV), sponsored by Sun Yat-sen University. Started Aug 2018; status: terminated.
02
Drugs
ranibizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02769169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02769169.